Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8EIB7
|
|||
| Drug Name |
MCY-M11
|
|||
| Drug Type |
CAR-PBMC Cell therapy
|
|||
| Indication | Fallopian tube cancer [ICD-11: 2C74; ICD-10: C57.0] | Phase 1 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [1] | ||
| Peritoneal cancer [ICD-11: 2C51.Z] | Phase 1 | [1] | ||
| Peritoneal mesothelioma [ICD-11: 2C51.2] | Phase 1 | [1] | ||
| Company |
MaxCyte
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mesothelin (MSLN) | Target Info | . | [2] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03608618) Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of MaxCyte. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.